Skip to content
Peptides Networkby Compounded Health
Menu

News

Peptide Compounding in 2026: What FDA Has and Has Not Decided

A dated record of FDA's actions on BPC-157, TB-500 and other peptides, as of October 18, 2026

4 min read Evidence checked October 18, 2026 Key takeaways 9 sources

In this article

Key takeaways

As of 2026-10-18, none of the seven peptides discussed at FDA's July 2026 compounding advisory meeting has been added to the 503A list, and FDA proposed that none be added. The committee's votes and FDA's final determination are not in the official records checked.

Evidence available
Regulatory documents
Confidence
High Every dated statement comes from an FDA web page, an FDA briefing document, the Federal Register or the eCFR.
Main limitation
FDA can act at any time; this page reflects the records available on 2026-10-18, which do not include the committee's votes.
Evidence checked See all 9 sources
AI-generated illustration: a glass mortar and pestle beside a teal glass bottle on a dark stone surface. Conceptual artwork.
AI-generated illustration · conceptual artwork

U.S. regulatory status

  • BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and Semax (bulk drug substances)

    Not FDA-approved

    Not on the 503A Bulks List in 21 CFR 216.23 (eCFR, 2026-10-15); FDA proposed in July 2026 that none be added

    Source 6, verified

As of 2026-10-18, FDA has not added BPC-157, TB-500, MOTS-c, KPV, Semax, epitalon or emideltide to the list of bulk drug substances that pharmacies may use for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act 6. For its advisory committee meeting on July 23 and 24, 2026, FDA proposed that none of them be added 3. FDA’s meeting page does not show how the committee voted, and the list in the Code of Federal Regulations has not changed since 2019 2,6. This page replaces a version first published in May 2026, whose headline said reclassification had opened the door for compounding pharmacies and which described the July meeting as still to come.

What FDA’s records show, in order

Before April 22, 2026. FDA’s page on bulk drug substances that may present significant safety risks lists 17 substances that had been in category 2 under FDA’s interim policies and whose nominations were then withdrawn by the nominators: AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu for injection, ipamorelin acetate, KPV, PEG-MGF, Melanotan II, MOTs-C, selank acetate, Semax, thymosin alpha-1 and TB-500 5. The page, last updated April 22, 2026, still gives FDA’s safety concerns for each, most often a possible immune reaction to the peptide and little or no human safety information. It does not give the dates of the withdrawals. Ipamorelin acetate also remains in category 2 for outsourcing facilities under section 503B 5.

April 15, 2026. An FDA page with this date announces that the Pharmacy Compounding Advisory Committee will meet before the end of February 2027 to discuss five more of these substances: cathelicidin LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF 7.

April 16, 2026. FDA announced the July meeting in the Federal Register (91 FR 20465) and opened public docket FDA-2025-N-6895 1.

July 23 and 24, 2026. The committee met; FDA’s meeting page links webcasts of both days 2. FDA asked for a vote on each substance: BPC-157, KPV, TB-500 and MOTS-c on July 23, and emideltide, epitalon and Semax on July 24, each in free-base and acetate form 2,4. That made 14 bulk drug substances from 7 peptides. For each of the 14, FDA’s briefing document states that FDA is proposing it not be included on the 503A list 3. FDA evaluated specific uses, for example ulcerative colitis for BPC-157, wound healing for TB-500, and obesity and osteoporosis for MOTS-c 2. Every nomination listed in the briefing document had been withdrawn by its nominator; FDA chose to present the substances anyway 3.

After the meeting. The meeting page, last updated August 6, 2026, lists FDA’s briefing documents, the questions, the final agenda and roster, and FDA’s presentations, but no vote results or minutes 2. The 503A list in 21 CFR 216.23, as in force on October 15, 2026, contains six substances, none of them peptides 6.

14 or 12?

The earlier version of this page said in one place that 14 of 19 restricted peptides would move toward compounding access, after an announcement it attributed to the HHS Secretary on February 27, 2026, and in another that 12 peptides were removed from category 2 on April 15, 2026. Neither the numbers nor the dates could be confirmed from FDA or Federal Register records, so they are removed. FDA’s own page lists 17 withdrawn substances 5. FDA has scheduled 12 of them for advisory committee review: 7 at the July 2026 meeting and 5 at the meeting planned before the end of February 2027 2,7. The July meeting covered 14 bulk drug substances because each of the 7 peptides was considered in two forms 2.

What a committee vote does and does not do

FDA describes advisory committee recommendations as non-binding: the agency generally follows them but is not legally bound to 2. Its briefing document says FDA does not intend to make a final determination until the committee’s input has been considered and all reviews are finalized 3. The 503A list is set by regulation 3, and it is published in 21 CFR 216.23 6.

One condition of section 503A is that a licensed pharmacist or physician compounds with bulk drug substances that meet a USP or NF monograph, are components of FDA-approved drugs, or appear on the 503A list 3,8. Being on that list would not make a compounded peptide an FDA-approved drug. The regulation states that representing a compounded drug made from a listed substance as FDA-approved, or as endorsed by FDA, makes it misbranded 6, and FDA states that compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed 9.

What is not yet known

  • How the committee voted on each substance; FDA had not posted results on the meeting page as of 2026-10-18 2.
  • Whether and when FDA will make a final determination on any of the seven peptides, and what it will be 3.
  • The date of the meeting on cathelicidin LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF 7.
  • Whether FDA plans to review the other five withdrawn substances (AOD-9604, CJC-1295, ipamorelin acetate, selank acetate and thymosin alpha-1); we found no scheduled review in FDA’s records.

This page does not assess whether any particular compounded product is lawful.

Topics

  • FDA
  • compounding
  • BPC-157
  • TB-500
  • regulation
  • news

Sources

9 sources. Numbers in the text link to the entry they cite.

  1. 1.
    Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List (91 FR 20465)

    U.S. Food and Drug Administration. Federal Register. 2026.

    Regulatory documentfederalregister.govChecked October 18, 2026

    Cited for: Federal Register notice published 2026-04-16 announcing the July 23-24, 2026 meeting; docket FDA-2025-N-6895

    Back to text

  2. 2.
    July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of 08/06/2026)

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: Agenda by day (BPC-157, KPV, TB-500, MOTs-C on July 23; emideltide, Semax, epitalon on July 24), free base and acetate forms; uses evaluated; advisory committees make non-binding recommendations; webcast links for both days; event materials list without vote results or minutes

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)Back to text (h)Back to text (i)

  3. 3.
    July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document Introduction

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: Section 503A bulk drug substance conditions; 503A Bulks List developed through regulations; nominations withdrawn but FDA elected to proceed; FDA proposing each of the 14 bulk drug substances NOT be included; no final determination until committee input considered and reviews finalized

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)Back to text (f)Back to text (g)

  4. 4.
    July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee - Questions

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: A vote question for each substance and form: 'Should ... be placed on the list?'

    Back to text

  5. 5.
    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026)

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: 17 bulk drug substances listed as previously in category 2 and withdrawn by the nominators; safety concerns for each; ipamorelin acetate also in 503B category 2

    Back to text (a)Back to text (b)Back to text (c)

  6. 6.
    21 CFR 216.23: Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act (eCFR, as of 2026-10-15)

    U.S. Food and Drug Administration. eCFR. 2019.

    Regulatory documentecfr.govChecked October 18, 2026

    Cited for: Six listed substances (Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, thymol iodide); representing a compounded drug as FDA approved causes misbranding; last amended 84 FR 4710 (2019)

    Back to text (a)Back to text (b)Back to text (c)Back to text (d)Back to text (e)

  7. 7.
    Meeting of the Pharmacy Compounding Advisory Committee (early announcement; content current as of 04/15/2026)

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: Next PCAC meeting before the end of February 2027 on cathelicidin LL-37, GHK-Cu, dihexa acetate, Melanotan II and PEG-MGF; date not yet scheduled

    Back to text (a)Back to text (b)Back to text (c)

  8. 8.
    Bulk Drug Substances Used in Compounding (content current as of 03/26/2026)

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: 503A compounders may only use bulk drug substances that meet a USP/NF monograph, are components of FDA-approved drugs, or appear on the 503A bulks list

    Back to text

  9. 9.
    Understanding the Risks of Compounded Drugs

    U.S. Food and Drug Administration. fda.gov. 2026.

    Regulatory documentfda.govChecked October 18, 2026

    Cited for: Compounded drugs are not FDA-approved; FDA does not review their safety, effectiveness or quality before they are marketed

    Back to text

Next read

Follow Compounded Health InstagramFacebook

Back to Peptides Network Back to top